https://www.live-feeds.com/feed/glp-1-drugs-appear-to-prevent-cancer-new-research-findsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/glp-1-drugs-appear-to-prevent-cancer-new-research-findshttps://www.live-feeds.com/feed/glp-1-drugs-appear-to-prevent-cancer-new-research-finds#u1667Tue, 16 Jun 2026 20:22:51 +0000Emerging research indicates GLP-1 receptor agonists like Ozempic and Wegovy may reduce the risk of obesity-related cancers, including breast, colorectal, pancreatic, and endometrial cancers. Studies suggest risk reductions ranging from 30% to 47% for breast cancer and broader mortality benefits in solid tumor patients. Scientists are investigating mechanisms behind these effects, with potential implications beyond weight loss.What's confirmed:GLP-1 receptor agonists, including semaglutide and tirzepatide, are associated with a 30–47% lower risk of breast cancer in women.Patients with solid tum